- Home
- ACIC vs ERAS Comparison
ACIC vs ERAS Comparison
Compare ACIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | ERAS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.1M | 1.0B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACIC | ERAS |
|---|---|---|
| Price | $11.41 | $15.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 223.3K | ★ 4.2M |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | ★ 39.61 | 36.23 |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | $5.26 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.97 | $1.01 |
| 52 Week High | $13.06 | $16.14 |
Technical Indicators
Market Signals| Indicator | ACIC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 64.22 |
| Support Level | $10.97 | $1.50 |
| Resistance Level | $11.85 | $16.14 |
| Average True Range (ATR) | 0.25 | 1.09 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 55.97 | 87.52 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.